NexgenRx ( (TSE:NXG) ) has shared an announcement.
NexgenRx reported strong financial results for 2024, with a 19% increase in revenue to $16,475,286 and a positive EBITDA of $2,339,422. The company is well-positioned for future growth, supported by its strong cash position and recurring revenues. NexgenRx plans to expand its market presence with innovative product solutions, leveraging its technology-driven offerings to meet increased demand for efficient benefits administration and claims processing.
More about NexgenRx
NexgenRx is Canada’s only independent full-service Third-Party Administrator and Technology Solutions Provider. The company offers proprietary capabilities in eligibility, enrolment, hour bank, mobile access, and claims adjudication, providing sophisticated administration and health benefit technology applications in a cost-effective SaaS model.
YTD Price Performance: -10.71%
Average Trading Volume: 51,008
Technical Sentiment Signal: Buy
Current Market Cap: C$18.7M
See more data about NXG stock on TipRanks’ Stock Analysis page.